B+
Bull case
0%
Probability
Target price
$265.86
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
STE
STERISBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$185.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+68.0
Score
AI commentary
News tone is modestly positive following the August earnings release, but analyst revision data, options data, short interest and social coverage are unavailable in the packet. The September valuation commentary was neutral-to-cautious, so the positive deterministic prior is best treated as a monitoring view rather than a high-conviction signal.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-08-05eventFY2027 Q1 earnings confirmed stable demandMedium impact
Revenue rose 7%, constant-currency organic revenue rose 6%, adjusted EPS increased to $2.59, and full-year revenue and earnings expectations were unchanged. Healthcare growth was led by services and consumables, with solid capital-equipment orders. [#SEC-8K-2026-08-05]
2026-12-08catalystTariff, inflation and AST capital-equipment pressureHigh impact
Healthcare operating income benefited from volume, price, productivity and mix but was partly offset by inflation and higher tariff costs. AST capital-equipment revenue declined 13% year over year, creating near-term margin and growth sensitivity. [#SEC-8K-2026-08-05]
2027-09-09catalystHealthcare share gains and recurring-revenue growthHigh impact
Management cited share gains in consumables and services, improved volume, pricing, productivity and mix, plus solid capital-equipment order growth. Execution in these areas could support continued earnings compounding. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology